Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) has completed the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to the company’s R&D Vancouver facility.

Following approval by the Gabonese government under the international Nagoya Protocol (see Filament’s stance regarding sustainable supply) as well as the country’s Convention on Biological Diversity, the botanical raw material was shipped to Canada for analysis and development into ibogaine extract.

Filament will work together with iboga-expert company Terragnosis to transform the root into a total-alkaloid extract, whose founder Jonathan Dickinson is convinced the agreement …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.